CPCornel Popovici

Cornel Popovici

*This is an algorithmically generated author record based on publicly available information.

Cornel Popovici has a total of 402 co-authors. Here are the top co-authors by number of shared publications:

  • Max Chaffanet

    Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Inserm UMR 1068, CNRS UMR 7258, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France

    19 shared publications
  • Daniel Birnbaum

    Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Inserm UMR 1068, CNRS UMR 7258, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France

    18 shared publications
  • Daniel Birnbaum

    Predictive Oncology Laboratory, CRCM, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France

    13 shared publications
  • José Adélaïde

    Predictive Oncology Laboratory, CRCM, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France

    11 shared publications
  • François Bertucci

    Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, France

    9 shared publications
  • Christophe Ginestier

    CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Aix-Marseille University, Epithelial Stem Cells and Cancer Laboratory, Equipe labellisée LIGUE contre le cancer, Marseille, France

    8 shared publications

Latest Publications

  • Open Access

    ESR1 Y537S Detected in a Brain Metastasis but Not in Plasma ctDNA in HR+/HER2-Low Metastatic Breast Cancer: A Case Report

    by Aemélia Nègre, Lorène Seguin, Arthur Géraud Cremieux, Frederic Viret, Agnès Tallet, Cornel Popovici, Anthony Gonçalves, Alexandre de Nonneville

    Brain metastases in hormone receptor-positive metastatic breast cancer remain incompletely characterized at the molecular level. We report isolated central nervous system progression in a 60-year-old woman with hormone receptor-positive breast cancer initially diagnosed at the age of 38 and metastatic recurrence diagnosed at the age of 55. After approximately five years of extracranial disease control with letrozole plus palbociclib, she developed multiple brain metastases, including a large cerebellar lesion requiring surgical resection. Molecular profiling of the resected lesion identified ESR1 Y537S and ERBB2 Y772_A775dup, whereas postoperative plasma circulating tumor DNA analyzed using a sensitive next-generation sequencing assay showed no detectable somatic alteration. Extracranial disease remained in complete metabolic response. This tissue–plasma discordance is compatible with spatial genomic heterogeneity but may also reflect a low circulating tumor fraction, postoperative reduction in tumor burden, and limited release of tumor-derived DNA from CNS lesions into the systemic circulation. This case highlights the limitations of plasma circulating tumor DNA for evaluating CNS-limited progression and supports direct molecular profiling of brain metastases when tissue is available.

  • Open Access

    Inhibition of the STAT3/Fanconi anemia axis is synthetic lethal with PARP inhibition in breast cancer

    by Celia D. Rouault, Lucile Bansard, Elena Martínez-Balsalobre, Caroline Bonnet, Julien Wicinski, Shuheng Lin, Ludovic Colombeau, Sylvain Debieu, Guillaume Pinna, Marie Vandamme, et al.

    The targeting of cancer stem cells (CSCs) has proven to be an effective approach for limiting tumor progression, thus necessitating the identification of new drugs with anti-CSC activity. Through a high-throughput drug repositioning screen, we identify the antibiotic Nifuroxazide (NIF) as a potent anti-CSC compound. Utilizing a click chemistry strategy, we demonstrate that NIF is a prodrug that is specifically bioactivated in breast CSCs. Mechanistically, NIF-induced CSC death is a result of a synergistic action that combines the generation of DNA interstrand crosslinks with the inhibition of the Fanconi anemia (FA) pathway activity. NIF treatment mimics FA-deficiency through the inhibition of STAT3, which we identify as a non-canonical transcription factor of FA-related genes. NIF induces a chemical HRDness (Homologous Recombination Deficiency) in CSCs that (re)sensitizes breast cancers with innate or acquired resistance to PARP inhibitor (PARPi) in patient-derived xenograft models. Our results suggest that NIF may be useful in combination with PARPi for the treatment of breast tumors, regardless of their HRD status.


  • Open Access

    Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial

    by Emilien Billon, Gwenaelle Gravis, Arnaud Guille, Nadine Carbuccia, Jose Adelaide, Séverine Garnier, Pascal Finetti, Emilie Denicolaï, Patrick Sfumato, Serge Brunelle, et al.

    Introduction. The prognosis of advanced urological cancers (AUC) remains unfavorable, and few data are available regarding precision medicine. Methods: the PERMED-01 prospective clinical trial assessed the impact of molecular profiling in adults with refractory advanced solid cancer, in terms of number of patients with tumor actionable genetic alterations (AGA), feasibility, description of molecular alterations, treatment, and clinical outcome. We present here those results in the 64 patients enrolled with AUC. DNA extracted from a new tumor biopsy was profiled in real-time (targeted NGS, whole-genome array-comparative genomic hybridization), and the results were discussed during a weekly molecular tumor board meeting. Results: a complete molecular profile was obtained in 49 patients (77%). Thirty-eight (59%) had at least one AGA. Twelve (19%) received a matched therapy on progression, of which 42% had a PFS2/PFS1 ratio ≥ 1.3 versus 5% in the “non-matched therapy group” (n = 25). The objective response and disease control rates were higher in the “matched therapy group” (33% and 58%, respectively) than in the “non-matched therapy group” (13% and 22%), as was the 6-month OS (75% vs. 42%). Conclusion: the profiling of a newly biopsied tumor sample identified AGA in 59% of patients with AUC, led to “matched therapy” in 19%, and provided clinical benefit in 8%.


  • TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients

    by Cecile Vicier, Patrick Sfumato, Nicolas Isambert, Florence Dalenc, Marie Robert, Christelle Levy, Keyvan Rezai, Magali Provansal, José Adélaïde, Séverine Garnier, et al.


  • Open Access

    TUMOSPEC: A Nation-Wide Study of Hereditary Breast and Ovarian Cancer Families with a Predicted Pathogenic Variant Identified through Multigene Panel Testing

    by Fabienne Lesueur, Séverine Eon-Marchais, Sarah Bonnet-Boissinot, Juana Beauvallet, Marie-Gabrielle Dondon, Lisa Golmard, Etienne Rouleau, Céline Garrec, Mathilde Martinez, Christine Toulas, et al.

    Assessment of age-dependent cancer risk for carriers of a predicted pathogenic variant (PPV) is often hampered by biases in data collection, with a frequent under-representation of cancer-free PPV carriers. TUMOSPEC was designed to estimate the cumulative risk of cancer for carriers of a PPV in a gene that is usually tested in a hereditary breast and ovarian cancer context. Index cases are enrolled consecutively among patients who undergo genetic testing as part of their care plan in France. First- and second-degree relatives and cousins of PPV carriers are invited to participate whether they are affected by cancer or not, and genotyped for the familial PPV. Clinical, family and epidemiological data are collected, and all data including sequencing data are centralized at the coordinating centre. The three-year feasibility study included 4431 prospective index cases, with 19.1% of them carrying a PPV. When invited by the coordinating centre, 65.3% of the relatives of index cases (5.7 relatives per family, on average) accepted the invitation to participate. The study logistics were well adapted to clinical and laboratory constraints, and collaboration between partners (clinicians, biologists, coordinating centre and participants) was smooth. Hence, TUMOSPEC is being pursued, with the aim of optimizing clinical management guidelines specific to each gene.


  • Open Access

    Bernard–Soulier syndrome: first human case due to a homozygous deletion of GP9 gene

    by Dorsaf Ghalloussi, Caroline Rousset‐Rouvière, Cornel Popovici, Florentine Garaix, Noémie Saut, Paul Saultier, Michel Tsimaratos, Hervé Chambost, Marie‐Christine Alessi, Véronique Baccini


  • Major Response to Carboplatin in a Patient With Metastatic Triple-Negative Breast Cancer With Somatic Mutation of BRCA1 and Loss of RAD51B

    by Lorène Seguin, Max Chaffanet, Séverine Garnier, José Adélaïde, Nadine Carbuccia, Arnaud Guille, Jihane Pakradouni, Renaud Sabatier, Cornel Popovici, Daniel Birnbaum, et al.

  • CDKN2A/B Deletion and Double-hit Mutations of the MAPK Pathway Underlie the Aggressive Behavior of Langerhans Cell Tumors

    by Luc Xerri, José Msc Adélaïde, Cornel Popovici, Séverine Garnier, Arnaud Msc Guille, Lenaïg Mescam-Mancini, Camille Laurent, Pierre Brousset, Carole Coze, Gérard Michel, et al.

    Langerhans cell histiocytosis (LCH) has a mostly favorable outcome, whereas Langerhans cell sarcoma (LCS) is an aggressive tumor. It is still unclear whether any specific molecular alterations could underlie the aggressive behavior of Langerhans cell proliferations. We used targeted next-generation sequencing and array-comparative genomic hybridization to profile 22 LCH samples from different patients together with 3 LCS samples corresponding to different relapses from the same patient. The third LCS relapse was a composite tumor including both B-cell chronic lymphocytic leukemia and LCS components. The 22 LCH samples were mostly of bone origin and showed classic histophenotypical features. Array-comparative genomic hybridization showed in all 3 LCS samples a similar homozygous somatic loss affecting the CDKN2A/B locus, whereas the 17 informative LCH samples did not show any detectable abnormality. In the 3 LCS samples, targeted next-generation sequencing of 495 cancer genes detected common mutations in KMT2D/MLL2 and in both MAP2K1 and NRAS genes, whereas BRAF was not mutated. A NOTCH1 mutation was acquired in 2 LCS samples. The composite LCS/B-cell chronic lymphocytic leukemia tumor showed the same genetic profile in its 2 components. LCH samples showed mutually exclusive mutations of BRAF (8/20) and MAP2K1 (4/19), but no mutation of KMT2D, NRAS nor NOTCH1. These results suggest that CDKN2A/B deletion and/or simultaneous mutations of MAP2K1 and NRAS may underlie the aggressive behavior of Langerhans cell tumors, and thus could be useful for the diagnosis of malignancy in histiocytic neoplasms. The MAPK pathway “double hit” profile provides a basis for targeted therapy in LCS patients.


  • Open Access

    Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study

    by Anthony Gonçalves, François Bertucci, Arnaud Guille, Severine Garnier, José Adelaide, Nadine Carbuccia, Oliver Cabaud, Pascal Finetti, Serge Brunelle, Gilles Piana, et al.

    Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study


  • Un cystadénocarcinome séreux du pancréas dans une variante solide

    by Nicolas Brandone, Flora Poizat, Jeanne Thomassin-Piana, Olivier Turrini, Cornel Popovici, Benoît Terris